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A matrix-assisted laser desorption/ionization Fourier transform mass spectrometry (MALDI-
FTMS)–based assay was developed for kinetic measurements and inhibitor screening of
acetylcholinesterase. Here, FTMS coupled to MALDI was applied to quantitative analysis of
choline using the ratio of choline/acetylcholine without the use of additional internal
standard, which simplified the experiment. The Michaelis constant (Km) of acetylcholinesterase
(AChE) was determined to be 73.9 mol L1 by this approach. For Huperzine A, the linear
mixed inhibition of AChE reflected the presence of competitive and noncompetitive compo-
nents. The half maximal inhibitory concentration (IC50) value of galantamine obtained for
AChE was 2.39 mol L1. Inhibitory potentials of Rhizoma Coptidis extracts were identified
with the present method. In light of the results the referred extracts as a whole showed
inhibitory action against AChE. The use of high-resolution FTMS largely eliminated the
interference with the determination of ACh and Ch, produced by the low-mass compounds of
chemical libraries for inhibitor screening. The excellent correlation with the reported kinetic
parameters confirms that the MS-based assay is both accurate and precise for determining
kinetic constants and for identifying enzyme inhibitors. The obvious advantages were
demonstrated for quantitative analysis and also high-throughput characterization. This study
offers a perspective into the utility of MALDI-FTMS as an alternate quantitative tool for
inhibitor screening of AChE. (J Am Soc Mass Spectrom 2008, 19, 1849–1855) © 2008
Published by Elsevier Inc. on behalf of American Society for Mass SpectrometryEnzymatic conversions play a crucial role in theregulation of all processes of life [1]. Enzymes arean important class of targets for treatment of
various diseases, such as cancer, diabetes, AIDs, and
hypertension [2–4]. Because of the potential use of
enzyme inhibitors as therapeutic agents, there is a
general interest in development of screening proce-
dures to identify novel enzyme inhibitors [5]. Acetyl-
cholinesterase (AChE) rapidly catalyzes the transfor-
mation of the active neurotransmitter acetylcholine
(ACh) into the inactive compounds choline (Ch) and
acetic acid (Scheme 1). Inhibition of acetylcholinest-
erase is considered a promising strategy for the
treatment of neurological disorders such as Alzhei-
mer’s disease (AD), senile dementia, ataxia, and
myasthenia gravis [6, 7].
The classical approaches for screening potential in-
hibitors are frequently based on UV-Vis absorbance,
fluorescence spectroscopy, or radioactivity detection
Address reprint requests to Dr. Yinlong Guo, Chinese Academy of Science,
Shanghai Mass Spectrometry Center, Shanghai Institute of Organic Chem-
istry, Shanghai 200032, China. E-mail: ylguo@mail.sioc.ac.cn
© 2008 Published by Elsevier Inc. on behalf of American Society for M
1044-0305/08/$32.00
doi:10.1016/j.jasms.2008.07.025[8–10]. The traditional spectrometric method for assay-
ing AChE activity was developed by Ellman and co-
workers [11]. This method was in an indirect manner
that the surrogate substrate acetylthiocholine and Ell-
man’s reagent should be used. In recent years, mass
spectrometry (MS)–based assays have attracted great
attention for high-throughput screening. MS offers the
significant advantage that it does not require analytes to
be labeled, either by direct attachment of fluorescent
and radioactive labels or by binding of antibodies, and
therefore offers greater flexibility in experiments [12–
14]. In the past decade, considerable effort was invested
to develop MS-based detection schemes capable of
assaying inhibition of enzyme-mediated reactions [15,
16]. The use of electrospray ionization (ESI)-MS is
rapidly expanding into the study of enzyme kinetics
[17–23]. Also, combinations of chromatographic and
electrophoretic separation methods with ESI-MS, such
as liquid chromatography (LC)/MS [24], LC/tandem
mass spectroscopy (MS/MS) [25], gas chromatography
(GC)/MS [26], frontal affinity chromatography (FAC)/MS
[27], or capillary electrophoresis (CE)/MS [28] have
been reported for the determination of acetylcholine
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are quite specific but have longer cycle times. Some
strategies based on immobilization enzyme have
been used for screening of enzyme inhibitors. Be-
cause of the low dissociation rates of some inhibitors,
however, it is difficult to achieve high-throughput
screening [29, 30].
Recently, because of its high speed, low sample
consumption, and high sensitivity, quantitative matrix-
assisted laser desorption/ionization (MALDI)-MS has
been widely developed in most fields of life science
for high-mass biomolecules. It is now also applied
as a tool for the quantification of low molecular
weight compounds of biological interest. Assaying
enzyme-inhibition reactions has also been shown
using matrix-free laser desorption/ionization process
on porous silicon (DIOS) [31, 32] and MALDI-MS
using a matrix of oxidized carbon nanotubes [33].
Fourier transform mass spectrometry (FTMS) was
introduced to couple with MALDI because of its
remarkable mass resolution and accuracy. Compared
to other mass spectrometers, the use of FTMS as the
detection system allows the production of highly accu-
rate mass spectra of target compounds. Accurate mass
determination and elemental composition data calcu-
lated thereby can be used for structure elucidation.
Large amounts of compounds and/or complex plant
extracts could be used for the inhibitor screening
against a given target. The compounds with molecular
weights in the region of enzyme substrate and product
(m/z  200, in this work) would interfere with monitor-
ing the enzymatic reaction; however, the high resolving
powers of FTMS enable us to detect compounds that are
close in mass/charge value. These advantages extend
the MS-based inhibitor screening to natural extracts,
without the need of sample purification step before MS
analysis.
The present investigation focused on the quantifica-
tion of the product of enzymatic reaction using sub-
strate as internal standard, thus eliminating the need for
addition of an internal standard. Herein we demon-
strate the applicability of a MALDI-FTMS–based assay
in the kinetics study and inhibitor screening of acetyl-
cholinesterase. We also apply the methodology to three
drugs targeting the acetylcholinesterase, including
Reminyl (galantamine hydrobromide), Excelon (riv-
astigmine tartrate), and Huperzine A. Then, we evalu-
ate the effect of Rhizoma Coptidis extracts on the
Scheme 1. Acetylcholinesterase converts acetylcholine into cho-
line and acetic acid.activity of AChE.Experimental
Reagents
All chemical reagents were obtained from commercial
suppliers and used without further purification. Acetyl-
cholinesterase from Electrophorus electricus (type VI-S,
EC 3.1.1.7, AChE), acetylcholine chloride, choline chlo-
ride, -cyano-4-hydroxycinnamic acid (CHCA), and
2,5-dihydroxybenzoic acid (DHB) were purchased from
Sigma Chemical Co. (St. Louis, MO, USA). Two AChE
inhibitors, galantamine hydrobromide and Huperzine
A, were provided by Kangjiu Chemical Co. (Shanghai,
China). Rivastigmine tartrate was kindly provided by
Prof. Xingxiang Xu of Shanghai Institute of Organic
Chemistry (Chinese Academy of Sciences, Shanghai).
Rhizoma Coptidis was purchased from Shanghai Tong-
Han-Chun-Tang Chinese Pharmacy (China). The deion-
ized water used in this study was from a Milli-Q water
purification system (Millipore Corp.; Bedford, MA,
USA). Acetonitrile and methanol were of HPLC-grade
quality purchased from Merck (Darmstadt, Germany).
PEG-200, PEG-400, acetone, dimethyl sulfoxide (DMSO),
and ethanol were bought from Shanghai Chemical
Reagent Corporation.
Sample Preparation
Sample solutions were prepared with 10 mM Tris-HCl
buffer (pH 7.5), except if indicated otherwise. The
matrix solution was prepared fresh daily by adding 150
mg of DHB to 1 mL of a methanol/water solution
(50/50, vol/vol). PEG-200 and PEG-400 were used as
external standards of mass calibration. The PEG-200
and PEG-400 solutions were prepared before experi-
ment in the mixture of water/methanol (50/50, vol/
vol) to the concentration of 10 g L1. Analytes for the
screening of enzyme inhibitors were normally dis-
solved in water or water/ethanol (1:1) with the concen-
tration of 1.0 mM. The solutions of Rhizoma Coptidis
dry powders (4 g) in different kinds of solvents (50 mL),
such as H2O, aceton, and dimethyl sulfoxide, were
refluxed at 110 °C for 2 h, respectively. The extracted
solutions were filtered and evaporated to dryness un-
der a gentle stream of nitrogen and the residue was
reconstituted in H2O.
MALDI-FTMS Conditions
Experiments were conducted using an Ionspec 4.7 T
HisRes MALDI-FTMS (Ionspec, Irvine, CA, USA). The
external Ionspec MALDI ion source used an air-cooled
Nd:YAG laser (355 nm, NewWave, Fremont, CA, USA)
with a gradient filter for adjusting the UV-laser power.
Ions, generated from a MALDI source, were transferred
via a quadrupole ion guide to the capacitively coupled
closed cylindrical cell. The intensity of MALDI-laser
irradiation was varied between 45% and 50% as needed.
The laser irradiation pulse time was set at 50 ms. For the
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voltage of 30 V (base to peak) at a frequency of 725 kHz.
The mass spectrometer was calibrated with PEG-200
and/or PEG-400 for each test. The acquisition mass
range was m/z 80–400. For the quantitative analysis, the
ratio of ACh to Ch was acquired by averaging six
separate spectra, each obtained from a single laser shot.
Two commonly used MALDI matrices, CHCA and
DHB, were examined for better ionization efficiency.
The matrix solution was deposited on the stainless
steel target to produce a microcrystalline layer of ma-
trix, followed by sample deposition onto the preformed
matrix layer. After the sample spots had dried com-
pletely, each one was overlaid with 1.0 L of matrix
solution, which produced a thin film of homogeneous
crystals.
Enzyme Kinetic Assay
All enzyme assays were carried out in 384-well micro-
titer plates in an assay volume of 40 L at 37 °C. The
reaction mixture of AChE, candidate chemicals (when
to determinate the kinetic parameters Km, the candidate
chemical solution was replaced by 10 mM Tris-HCl
buffer), and acetylcholine was incubated for 60 min,
except if indicated otherwise. Acetonitrile (30 L) was
then added to the mixture to quench the reaction. To
measure the Km of the nature substrate ACh, the con-
version percentages of acetylcholine (0.07, 0.15, 0.33,
0.37, and 0.44 mM) to choline were calculated at differ-
ent reaction times.
Results and Discussion
MALDI-FTMS Analysis
Among the matrices tested (DHB, CHCA, or a mixture
of both), DHB gave the best results for the acetylcholine
and choline. Figure 1 depicts a typical spectrum ob-
tained by mixing acetylcholine and choline in equal
molar ratio. As shown, the signals of substrate [ACh]
(m/z 146.1174) and of product [Ch] (m/z 104.1071) are
clearly recognizable, allowing the measurement of low
Figure 1. The MALDI-FTMS spectrum obtained for a mixture of
acetylcholine (m/z 146) and choline (m/z 104) in equal molar ratio.molecular mass compounds. The signal of Ch was
detected with a mass resolution of 78,100, ACh with a
mass resolution of 55,300, and the ion of m/z 87 with a
mass resolution of 92,600. Ions of the compounds of
interest were confirmed by the standards, respectively,
to eliminate the interference from the candidate chem-
icals (pure chemical or complex mixture).
As shown in Figure 1, the ion signal of m/z 87 was
detected, which was thought to result from the frag-
mentation of acetylcholine (m/z 146). The fragmentation
pattern observed for the signal m/z 146 under MALDI-
FTMS (Figure 1) caused by laser energy is in accordance
with that observed in ESI-MS/MS. It has been proposed
that the structure of the ion m/z 87 is either a cation (m/z
87.0441) [34–37] or a radical cation (m/z 87.1043) [25]
(Scheme 2).
By decreasing the laser energy until no signals of
ACh and Ch are observed, the fragment of ACh is still
observed. The accurate mass measured was 87.0440
[percentage relative standard deviation (%RSD) 
0.008, n  6], which deviated from the calculated mass
of the cation (87.0441) by 1.15 ppm, indicating that the
product ion m/z 87 is a cation. It consists mainly in the
elimination of N(CH3)3 of 59u, giving the fragment ion
ofm/z 87. Besides the two structures (Scheme 2, a and b)
proposed in previous studies, a five-member cyclic
acylium ion (Scheme 2,c) is also possible. B3LYP/6-
31G(d) density functional calculations, as implemented
in Gaussian 03 [38], were used to determine the relative
energies of the three possible cation structures. The
energies listed in Scheme 2 suggested that a would be
173.7 kJ/mol higher in energy relative to acylium ion c,
and b would be 81.6 kJ/mol higher than c. Thus, the
fragmentation of ACh is more likely to form the cation
c, which is more favorable in energy.
Calibration and Quantification by MALDI-FTMS
In the presence of acetylcholinesterase, acetylcholine is
completely converted to choline, corresponding to a
change in molecular mass from 146 to 104. The presence
of AChE does not interfere with the detection of any of
the small molecules of interest. Relative peak–height
ratios of product to substrate determined by MALDI-
FTMS allow the quantitative analysis of enzymatic
reaction for screening purposes. Usually six to eight
positions from one sample spot were used for the
average. As shown in Scheme 2, the fragmentation of
ACh could produce the ion signal of m/z 87. It was
necessary to find a proper ion signal to indicate the
amount of ACh from the mass spectrum. Thus, three
different ion signals (m/z 87, m/z 146, and the sum of
both) were investigated. Relative intensities of [Ch] to
[ACh  N(CH3)3]
, [ACh] and  ([ACh  N(CH3)3],
[ACh]), respectively, were obtained for the calibration
curve of product (Figure 2). Calibration curves were
established by plotting the intensity ratios against the
choline concentration in the sample solution (0.02–311
mmol L1). The concentration of the acetylcholine (in-
1852 XU ET AL. J Am Soc Mass Spectrom 2008, 19, 1849–1855ternal standard) was 3.89 mmol L1. From the resulting
calibration curve the regression coefficient, y-intercept
and slope were calculated, characterizing the calibra-
tion function.
The data points of curve a in Figure 2 showed large
error bars and poor correlation coefficient (r  0.9897),
compared with curves b and c. The calibration curve
(Figure 2c) by plotting the intensity ratio of [Ch] to
 ([ACh  N(CH3)3], [ACh]) against the concentra-
Scheme 2. Different conceivable fragmentatio
energies listed below the structures of three poss
functional calculations.
Figure 2. Calibration curves of intensity ratio versus the concen-
tration of choline established for three different relative intensities
(the fragment of acetylcholine, acetylcholine, or both of them).
From the calibration curve, X means the concentration of choline:
(a) Y means the relative intensity of [Ch] to [ACh  N(CH3)3]
,
Y  0.5984  0.0989X, r  0.9897; (b) Y means the relative
intensity of [Ch]  to [ACh], Y  0.1306  0.0448X, r  0.9966;
(c) Y means the relative intensity of [Ch]  to  ([ACh 
N(CH3)3]
, [ACh]), Y  0.1145  0.0305X, r  0.9966. Calibra-
tion curves were established by plotting the intensity ratios
against the choline concentration in the sample solution (0.02–311
mmol L1). The concentration of the acetylcholine (internal stan-
dard) was 3.89 mmol L1. The data points displayed represent the
mean for six replicate measurements.tion of choline was linear over five orders of magnitude,
ranging from 0.02 to 311 mmol L1 of choline, with a
correlation coefficient of 0.9966. This result showed
high accuracy and good reproducibility. The relative
intensity of [Ch] to [ACh] (Figure 2b) also gave
reliable calibration curves (r  0.9966), although with a
worse reproducibility. So, the intensities ratio of [Ch] to
 ([ACh  N(CH3)3], [ACh]) (Figure 2c) is used to
quantitative detection of choline in the following
section.
The limits of detection and quantification (LOD and
LOQ, respectively) were determined by analyzing a
series of standard solutions until the signal-to-noise
(S/N) ratio for each compound was around 3 for LOD
and 10 for LOQ. LOD for the MALDI-FTMS analysis
was determined as 2.44 picomolar (pM) for acetylcho-
line and 6.09 pM for choline. LOQ was 9.74 and 19.77
pM for acetylcholine and choline, respectively.
Determination of the Michaelis Constant (Km) for
Acetylcholinesterase
Enzyme reaction was monitored by MALDI-FTMS
analysis. It was possible to follow the reaction over time
by monitoring the decrease of signal intensity of acetyl-
choline and the increase of that of choline (Figure 3).
According to the calibration curve constructed earlier,
the conversion percentages of acetylcholine to choline
were calculated at different reaction times. Under the
conditions used in this study, the conversion of acetyl-
choline is roughly 55% after 40 min of reaction. To
increase the screening throughput, a high-concentration
solution of acetylcholinesterase (1.4 mol L1) could be
used for the following experiments. In this case, AChE
could completely transform ACh to Ch in 1 h.
Initial velocities of enzymatic reaction are measured
by change in product Ch amounts with time at the
linear region of the process curve. The average reaction
tterns for acetylcholine in MALDI-FTMS. The
ations are based on the B3LYP/6-31G(d) densityn pa
ible cvelocity within the first 20 min was considered as the
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sample). To determine Km, the reaction must be run
using a range of substrate concentrations (from 0.07 to
0.44 mM). The initial velocity of the reaction is then
determined for each concentration. A plot of 1/[initial
velocity] versus 1/[ACh] generates a Lineweaver-Burk
Figure 3. Process curve of choline formation as a function of
incubation time. The initial substrate concentration was 1.4 nmol
L1. Inset: Lineweaver-Burk plot of acetylcholinesterase. The
concentration of acetylcholine was varied from 0.07 to 0.48 mmol
L1 and the concentration of acetylcholinesterase was kept at 1.4
mol L1. From Lineweaver-Burk plot, Km slope/intercept. The
reaction was performed at 37 °C.
Figure 4. (a) The mass spectra for screening o
drugs and Rhizoma Coptidis extracts. (b) The m
different solvents (top, DMSO; middle, H O; bot2
of three Rhizoma Coptidis extracts, respectively (topplot and a linear regression fit to this data is then used
to estimate the Km (Km  slope/intercept). The good
linearity of the Lineweaver-Burk plot for acetylcholine
shown in Figure 3 (inset) demonstrates the accuracy of
steady-state kinetics in this assay. The Michaelis con-
stant (Km) is defined as the substrate concentration at
which the reaction occurs at half of the maximum
velocity, with a value typically in the range of 101–
105 mol L1 [39]. The Km of acetylcholinesterase was
determined to be 73.9 mol L1. Values obtained using
the MALDI-FTMS–based assay are well within the
range of values reported in other studies (43 M [40], 61
M [41], 98 M [31], 0.23 mM [33], respectively).
Inhibition Kinetics
The screening of potential AChE inhibitors was per-
formed by monitoring the conversion ratio of ACh
in the presence of candidate compounds. Three com-
mercially available AChE inhibitors—Reminyl (galan-
tamine hydrobromide), Excelon (rivastigmine tartrate),
and Huperzine A—were used to evaluate the method-
ology individually. In the absence of inhibitor, the
reaction catalyzed by AChE could reach completion
within 60 min. While the active compound was added
to the reaction system, AChE could not catalyze the
complete transformation of ACh into Ch in 1 h. The
remaining ACh indicates the inhibition potency of
the compound. All three of them showed inhibitory
effects on the activity of AChE (Figure 4a). To test
whether the system was effective in a real screening
ibitors, including three commercially available
ectra of crude Rhizoma Coptidis extracts using
acetone). (c) Conversion of ACh in the presencef inh
ass sp
tom,, DMSO; middle, H2O; bottom, acetone).
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dis, which is a commonly used herb in Chinese medi-
cine. Berberine, the representative quaternary ammo-
nium alkaloid in commercial Rhizoma Coptidis, is an
AChE inhibitor [42]. Three solvents were used to extract
the active components from the dry powders of Rhi-
zoma Coptidis. As expected, Rhizoma Coptidis extracts
inhibited the activity of acetylcholinesterase by the
present method (Figure 4 a). By monitoring the conver-
sion percentage of ACh, the inhibitory activity of a
candidate compound can be determined. Low conver-
sion of ACh indicates the candidate compound shows
relative high inhibitory activity against AChE. As re-
vealed in Figure 4b, compared to water and acetone,
Figure 5. (a) Lineweaver-Burk plots for Huperzine A. The con-
centration of acetylcholine was varied from 0.07 to 0.48 mM and
the concentration of inhibitor Huperzine A was varied from 0.1 to
10 mM in log dilutions (––, 10 mM; –Œ–, 1 mM; –‘–, 0.1 mM).
––: Y 0.9028 0.1439X, r 0.9999; –Œ–: Y 0.7418 0.1154X,
r  0.9924; –‘–: Y  0.6531  0.0993X, r  0.9945. (b) Inhibition
plot of galantamine. The IC50 value displayed represents the mean
for six replicate measurements. The concentration of acetylcholine
was 0.7 mmol L1 and the concentration of acetylcholinesterase
was kept at 1.4 mol L1. The reactions were performed at 37 °C.berberine (m/z 336.1230) was more selectively extracted
using DMSO as solvent. In this case, the activity of
AChE was more significantly decreased. We can con-
clude that, depending on how the Rhizoma Coptidis
dry powders are extracted, because of the different
properties of solvents, the amount of effective compo-
nents can be altered, as well as the conversion efficiency
of ACh to Ch in the presence of AChE (Figure 4c).
The Lineweaver-Burk plots obtained at different
inhibitor concentrations for Huperzine A are shown in
Figure 5. The resulting plots showed that Huperzine A
displayed a mixed inhibition, with competitive and
noncompetitive inhibition behaviors. The obtained data
in our experiment are in accordance with the literature
[43]. The inhibition plot of galantamine is shown in
Figure 5b. The IC50 value of galantamine was deter-
mined as 2.39 M, which was comparable with the
literature values of 0.42 to 5 M (0.42 M for Torpedo
californica AChE [44], 0.61 M for Electrophorus electricus
AChE [44], 5 M for AChE in postmortem brain tissue
from AD patients [45]).
Conclusions
In this study, a MALDI-FTMS method for monitoring
enzyme reaction and screening of inhibitor against
acetylcholinesterase has been developed. MALDI-
FTMS can be easily and simply applied to study steady-
state kinetics for an acetylcholinesterase system. Com-
pared with other methods, the matrix used in this
report is simpler and easier to acquire. The extract mass
and high-resolution measurements by using FTMS as
detection system make it possible to extend this meth-
odology to complex mixtures and biological samples.
The small cost of the materials and a short time of
scanning required make this method an optimal choice
for high-throughput screening of inhibitors from a
library of compounds. We assume that this method
might be useful for other types of enzymes.
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